Solara notes Q3'26 API momentum despite Ibuprofen drag and announces strategic advisers to evaluate Ibuprofen options and re‑assess the CRAMS & Polymers split; roadmap to be shared next quarter.
AI Assistant
Solara Active Pharma Sciences Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.